Putnam Investments LLC Vertex Pharmaceuticals Inc Transaction History

Putnam Investments LLC

$73 Billion
Q4 2023

A detailed history of Putnam Investments LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Putnam Investments LLC holds 106,049 shares of VRTX stock, worth $43 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

106,049

Previous 109,128 2.82%

Holding current value

$43 Million

Previous $37.9 Million 13.71%

% of portfolio

0.06%

Previous 0.06%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$343.0 - $410.68 $1.06 Million - $1.26 Million	-3,079 Reduced 2.82%	106,049 $43.2 Million
Q3 2023 Nov 14, 2023	SELL	$338.18 - $362.46 $533,648 - $571,961	-1,578 Reduced 1.43%	109,128 $37.9 Million
Q2 2023 Aug 14, 2023	SELL	$314.42 - $351.91 $2.59 Million - $2.9 Million	-8,237 Reduced 6.93%	110,706 $39 Million
Q1 2023 May 22, 2023	SELL	$283.23 - $323.1 $4.26 Million - $4.86 Million	-15,029 Reduced 11.22%	118,943 $37.5 Million
Q4 2022 Feb 14, 2023	SELL	$285.76 - $321.48 $2.66 Million - $2.99 Million	-9,309 Reduced 6.5%	133,972 $38.7 Million
Q3 2022 Nov 14, 2022	SELL	$273.83 - $305.53 $12.4 Million - $13.8 Million	-45,221 Reduced 23.99%	143,281 $41.5 Million
Q2 2022 Aug 15, 2022	BUY	$234.96 - $292.55 $4.56 Million - $5.68 Million	19,420 Added 11.49%	188,502 $53.1 Million
Q1 2022 May 16, 2022	SELL	$221.42 - $260.97 $2.77 Million - $3.26 Million	-12,490 Reduced 6.88%	169,082 $44.1 Million
Q4 2021 Feb 14, 2022	SELL	$177.01 - $223.45 $59.7 Million - $75.4 Million	-337,467 Reduced 65.02%	181,572 $39.9 Million
Q3 2021 Nov 15, 2021	SELL	$181.39 - $202.99 $2 Million - $2.24 Million	-11,020 Reduced 2.08%	519,039 $94.1 Million
Q2 2021 Aug 16, 2021	BUY	$187.49 - $221.1 $9.12 Million - $10.8 Million	48,639 Added 10.1%	530,059 $107 Million
Q1 2021 May 17, 2021	SELL	$207.02 - $241.31 $185 Million - $216 Million	-893,233 Reduced 64.98%	481,420 $103 Million
Q4 2020 Feb 16, 2021	BUY	$207.01 - $276.09 $32.2 Million - $42.9 Million	155,467 Added 12.75%	1,374,653 $325 Million
Q3 2020 Nov 16, 2020	SELL	$255.65 - $303.1 $50.1 Million - $59.4 Million	-195,949 Reduced 13.85%	1,219,186 $332 Million
Q2 2020 Aug 14, 2020	BUY	$225.48 - $295.8 $10.3 Million - $13.6 Million	45,824 Added 3.35%	1,415,135 $411 Million
Q1 2020 May 15, 2020	BUY	$199.77 - $247.81 $50.8 Million - $63 Million	254,079 Added 22.78%	1,369,311 $326 Million
Q4 2019 Feb 14, 2020	SELL	$166.71 - $223.91 $21 Million - $28.2 Million	-126,087 Reduced 10.16%	1,115,232 $244 Million
Q3 2019 Nov 14, 2019	BUY	$166.23 - $187.09 $15.8 Million - $17.8 Million	95,195 Added 8.31%	1,241,319 $210 Million
Q2 2019 Aug 14, 2019	SELL	$164.61 - $190.37 $9.2 Million - $10.6 Million	-55,896 Reduced 4.65%	1,146,124 $210 Million
Q1 2019 May 15, 2019	SELL	$163.73 - $194.7 $42.9 Million - $51.1 Million	-262,303 Reduced 17.91%	1,202,020 $221 Million
Q4 2018 Feb 14, 2019	SELL	$151.91 - $192.21 $21.7 Million - $27.4 Million	-142,737 Reduced 8.88%	1,464,323 $243 Million
Q3 2018 Nov 14, 2018	SELL	$167.73 - $192.74 $24.3 Million - $27.9 Million	-144,700 Reduced 8.26%	1,607,060 $310 Million
Q2 2018 Aug 14, 2018	BUY	$145.72 - $169.96 $5.71 Million - $6.66 Million	39,166 Added 2.29%	1,751,760 $298 Million
Q1 2018 May 15, 2018	BUY	$151.6 - $177.13 $39.5 Million - $46.1 Million	260,431 Added 17.93%	1,712,594 $279 Million
Q4 2017 Feb 14, 2018	BUY	$137.28 - $155.55 $51.2 Million - $58 Million	372,722 Added 34.53%	1,452,163 $218 Million
Q3 2017 Nov 14, 2017	BUY	$148.13 - $162.24 $160 Million - $175 Million	1,079,441	1,079,441 $164 Million

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

221M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $104B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Putnam Investments LLC, based on Form 13F filings with the SEC.

News

Stay updated on Putnam Investments LLC with notifications on news.

Account

Putnam Investments LLC Vertex Pharmaceuticals Inc Transaction History